Jiangsu Hengrui Medicine Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ji Feng
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 3.5yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
CEO
Ji Feng (53 yo)
Ms. Ji Feng is GM, President and COO of Jiangsu Hengrui Medicine Co. Ltd. since April 28, 2025 and serves as its Executive Director since April 28, 2025. Ms. Feng joined the Jiangsu Hengrui Medicine Co. Lt...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 28.1yrs | CN¥1.65m | no data | |
| Executive Deputy Chairman of the Board | 5.3yrs | CN¥4.88m | 0.027% CN¥ 96.6m | |
| Chief Financial Officer | 3.5yrs | CN¥2.28m | no data | |
| Senior VP & Executive Director | no data | CN¥2.48m | 0.030% CN¥ 107.8m | |
| Executive VP & Executive Director | 13.1yrs | CN¥3.90m | 0.0078% CN¥ 28.1m | |
| Executive VP | 2.3yrs | CN¥4.25m | no data | |
| Joint Company Secretary | 9yrs | CN¥850.70k | 0.0014% CN¥ 5.0m | |
| Deputy General Manager | 12.1yrs | CN¥2.02m | 0.0050% CN¥ 17.8m | |
| Deputy General Manager | 4.6yrs | CN¥2.89m | 0.0026% CN¥ 9.3m | |
| Deputy General Manager | 2.6yrs | CN¥3.14m | 0.00020% CN¥ 718.7k | |
| Deputy General Manager | 2.3yrs | CN¥1.22m | 0.0012% CN¥ 4.3m | |
| GM, President | less than a year | no data | no data |
Experienced Management: 600276's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 28.1yrs | CN¥1.65m | no data | |
| Executive Deputy Chairman of the Board | 5.3yrs | CN¥4.88m | 0.027% CN¥ 96.6m | |
| Senior VP & Executive Director | 5.3yrs | CN¥2.48m | 0.030% CN¥ 107.8m | |
| Executive VP & Executive Director | 13.1yrs | CN¥3.90m | 0.0078% CN¥ 28.1m | |
| Executive VP | 2.3yrs | CN¥4.25m | no data | |
| GM, President | less than a year | no data | no data | |
| Chairman of the Supervisory Board | 2.3yrs | CN¥2.93m | 0.020% CN¥ 73.0m | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 2.3yrs | CN¥100.00k | no data | |
| Independent Non-Executive Director | 2.3yrs | CN¥100.00k | no data | |
| Non-Executive Director | 5.3yrs | no data | no data | |
| Independent Non-Executive Director | 4yrs | no data | no data |
Experienced Board: 600276's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 22:37 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jiangsu Hengrui Medicine Co., Ltd. is covered by 56 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Changming He | BOCI Research Ltd. |
| Bo Li | BofA Global Research |